Periodic Reporting for period 1 - AI4IVF (Artificial Intelligence for in vitro fertilisation.)
Reporting period: 2023-07-01 to 2024-12-31
Infertility affects 1 in 5 people, yet IVF remains costly and inconsistent. MIM Fertility provides evidence-based AI solutions to enhance decision-making, standardize care, and lower costs, improving accessibility.
We applied for AI FOR IVF funding to support marketing and ensure trust in our SaMD-certified AI. Backed by an international Scientific Advisory Board, our technology remains rigorous, validated, and clinically aligned.
Key Project Objectives
1. Establishing a Scientific Advisory Board (SAB):
AI adoption in IVF requires trust and credibility. The SAB consists of globally recognized reproductive medicine specialists who oversee and advise on AI implementation. The SAB members serve as project ambassadors, actively promoting our solutions and shaping the future of AI in IVF.
2. Building and Executing an Expert-Authored Content Marketing Strategy:
Content marketing is the most effective B2B engagement tool, fostering education and market trust. We developed a comprehensive strategy in collaboration with the SAB and industry experts, addressing common concerns, questions, and key talking points. This included creating expert-led blog content, launching the AI Academy, AI workshops, and producing educational materials to prepare and support the industry’s AI transition. As AI in IVF is still an emerging field, this initiative aims to educate, shift mindsets, and drive industry adoption.
3. Developing a Motivational Branding Strategy for Global Markets:
Introducing AI in IVF requires more than awareness—it demands daily integration into clinical practice. Our targeted branding approach positions AI as essential, not optional, through specialized messaging and dedicated communication channels. A strong presence at key industry events (e.g. ESHRE, ASRM) further reinforces AI’s real-world impact and builds trust among fertility professionals.
AI adoption in healthcare is a paradigm shift that necessitates support for professionals. Given the mental health burden in IVF, AI can reduce stress by alleviating workload and decision fatigue. However, technology alone is insufficient—trust, communication, and ongoing support are critical. Our compassionate strategy ensures AI is introduced in a way that resonates with the human side of fertility care, fostering both confidence and long-term adoption.
4.Building a Business Development Team for Market Penetration:
While marketing, content strategy, event participation, and communication create demand, a dedicated business development team is necessary to convert interest into sales. Our market research and strategic execution plan identified high-potential markets for AI adoption. A trained business development team ensures direct engagement with clinics, demonstrating how AI solutions improve workflows and patient success rates.
We applied for AI FOR IVF funding to support marketing and ensure trust in our SaMD-certified AI. Backed by an international Scientific Advisory Board, our technology remains rigorous, validated, and clinically aligned.
Key Project Objectives
1. Establishing a Scientific Advisory Board (SAB):
AI adoption in IVF requires trust and credibility. The SAB consists of globally recognized reproductive medicine specialists who oversee and advise on AI implementation. The SAB members serve as project ambassadors, actively promoting our solutions and shaping the future of AI in IVF.
2. Building and Executing an Expert-Authored Content Marketing Strategy:
Content marketing is the most effective B2B engagement tool, fostering education and market trust. We developed a comprehensive strategy in collaboration with the SAB and industry experts, addressing common concerns, questions, and key talking points. This included creating expert-led blog content, launching the AI Academy, AI workshops, and producing educational materials to prepare and support the industry’s AI transition. As AI in IVF is still an emerging field, this initiative aims to educate, shift mindsets, and drive industry adoption.
3. Developing a Motivational Branding Strategy for Global Markets:
Introducing AI in IVF requires more than awareness—it demands daily integration into clinical practice. Our targeted branding approach positions AI as essential, not optional, through specialized messaging and dedicated communication channels. A strong presence at key industry events (e.g. ESHRE, ASRM) further reinforces AI’s real-world impact and builds trust among fertility professionals.
AI adoption in healthcare is a paradigm shift that necessitates support for professionals. Given the mental health burden in IVF, AI can reduce stress by alleviating workload and decision fatigue. However, technology alone is insufficient—trust, communication, and ongoing support are critical. Our compassionate strategy ensures AI is introduced in a way that resonates with the human side of fertility care, fostering both confidence and long-term adoption.
4.Building a Business Development Team for Market Penetration:
While marketing, content strategy, event participation, and communication create demand, a dedicated business development team is necessary to convert interest into sales. Our market research and strategic execution plan identified high-potential markets for AI adoption. A trained business development team ensures direct engagement with clinics, demonstrating how AI solutions improve workflows and patient success rates.
Scientific and Technical Developments
1. Establishing a Multidisciplinary Scientific Advisory Board (SAB)
- Objective: Ensure AI solutions align with clinical needs and best practices by incorporating expert insights.
- Achievements:
- Appointed leading embryologists, reproductive medicine specialists, and AI experts from Europe, the USA, and Latin America as members of our SAB.
- Negotiated contracts and duties - appointed tasks.
- The SAB provided critical validation and guidance for EMBRYOAID and FOLLISCAN, ensuring usability and integration into IVF workflows.
- Actively participated in ESHRE 2024 and ASRM 2024, where members of the board have conducted workshops, panel discussions, and keynote presentations.
- Under our guidance SAB has engaged in scientific advocacy, producing research-backed insights to strengthen MIM Fertility’s credibility as an AI pioneer.
2. AI-Powered Content and Knowledge Dissemination
- Objective: Educate IVF professionals on AI applications, enhancing acceptance and implementation.
- Achievements:
- Launched AI Academy, providing hands-on training in AI tools for IVF clinics.
- Published 10+ expert-authored scientific blog posts explaining AI’s role in decision-making and embryo selection.
- Created infographics, webinars, and evidence-based educational content addressing key concerns in AI adoption.
- Increased LinkedIn engagement significantly (from 400 to 2,100 followers) within the grant period, demonstrating successful outreach efforts.
3. Developing a Motivational Branding Strategy
- Objective: Inspire fertility professionals to integrate AI into daily clinical practice by fostering trust and motivation.
- Achievements:
- Developed a human-centered, ethical branding strategy emphasizing AI’s benefits for clinicians and patients.
- Created localized marketing strategies for key IVF markets (Brazil, UK, Central & Eastern Europe).
- Ensured presence at industry-leading events (ESHRE, ASRM) to showcase AI innovations.
- Aligned messaging with scientific credibility and emotional connection, addressing concerns about AI in fertility care.
4. Business Development and Global Market Expansion
- Objective: Expand MIM Fertility’s reach by directly engaging with clinics and industry leaders.
- Achievements:
- Recruited and trained two Business Development Experts to support market entry and partnerships.
- Secured collaborations with Hamilton Thorne and ESCO, enhancing product credibility and reach.
- Held 90+ meetings at ESHRE 2024, leading to a strong sales pipeline and product trials in clinics across Romania, London, and South America.
Outcomes of the Action
- Strengthened scientific validation of AI tools through the Scientific Advisory Board.
- Expanded AI literacy within IVF clinics via the AI Academy and knowledge dissemination initiatives.
- Created a sustainable branding and educational strategy to promote AI adoption in IVF clinics.
- Established a robust business development framework, paving the way for continued commercialization.
1. Establishing a Multidisciplinary Scientific Advisory Board (SAB)
- Objective: Ensure AI solutions align with clinical needs and best practices by incorporating expert insights.
- Achievements:
- Appointed leading embryologists, reproductive medicine specialists, and AI experts from Europe, the USA, and Latin America as members of our SAB.
- Negotiated contracts and duties - appointed tasks.
- The SAB provided critical validation and guidance for EMBRYOAID and FOLLISCAN, ensuring usability and integration into IVF workflows.
- Actively participated in ESHRE 2024 and ASRM 2024, where members of the board have conducted workshops, panel discussions, and keynote presentations.
- Under our guidance SAB has engaged in scientific advocacy, producing research-backed insights to strengthen MIM Fertility’s credibility as an AI pioneer.
2. AI-Powered Content and Knowledge Dissemination
- Objective: Educate IVF professionals on AI applications, enhancing acceptance and implementation.
- Achievements:
- Launched AI Academy, providing hands-on training in AI tools for IVF clinics.
- Published 10+ expert-authored scientific blog posts explaining AI’s role in decision-making and embryo selection.
- Created infographics, webinars, and evidence-based educational content addressing key concerns in AI adoption.
- Increased LinkedIn engagement significantly (from 400 to 2,100 followers) within the grant period, demonstrating successful outreach efforts.
3. Developing a Motivational Branding Strategy
- Objective: Inspire fertility professionals to integrate AI into daily clinical practice by fostering trust and motivation.
- Achievements:
- Developed a human-centered, ethical branding strategy emphasizing AI’s benefits for clinicians and patients.
- Created localized marketing strategies for key IVF markets (Brazil, UK, Central & Eastern Europe).
- Ensured presence at industry-leading events (ESHRE, ASRM) to showcase AI innovations.
- Aligned messaging with scientific credibility and emotional connection, addressing concerns about AI in fertility care.
4. Business Development and Global Market Expansion
- Objective: Expand MIM Fertility’s reach by directly engaging with clinics and industry leaders.
- Achievements:
- Recruited and trained two Business Development Experts to support market entry and partnerships.
- Secured collaborations with Hamilton Thorne and ESCO, enhancing product credibility and reach.
- Held 90+ meetings at ESHRE 2024, leading to a strong sales pipeline and product trials in clinics across Romania, London, and South America.
Outcomes of the Action
- Strengthened scientific validation of AI tools through the Scientific Advisory Board.
- Expanded AI literacy within IVF clinics via the AI Academy and knowledge dissemination initiatives.
- Created a sustainable branding and educational strategy to promote AI adoption in IVF clinics.
- Established a robust business development framework, paving the way for continued commercialization.
MIM Fertility’s AI-driven solutions, EMBRYOAID and FOLLISCAN, represent a breakthrough in assisted reproductive technology (ART). These tools go beyond existing industry practices by introducing AI-powered decision support, workflow optimization, and clinical standardization, addressing key inefficiencies in fertility treatments.
Key advancements include:
- AI-Driven Embryo and Follicle Analysis: Introducing machine learning models that assist in embryo selection and follicle monitoring, improving the accuracy and reliability of IVF procedures.
- Integration with IVF Workflows: Seamless incorporation into laboratory and clinical environments, enhancing efficiency and reducing embryologists’ workload.
- Scientific Validation and Ethical AI Practices: Backed by a Scientific Advisory Board (SAB) of leading reproductive medicine specialists to ensure credibility and compliance with industry best practices.
Potential Impact and Future Needs
1. Further Research and Validation:
- Conducting large-scale clinical studies to assess AI’s long-term impact on IVF success rates.
- Continuous model refinement with real-world clinical data to enhance AI performance and accuracy.
2. Commercialization and Market Adoption:
- Expanding regulatory approvals, including CE marking (EU) and FDA clearance (US).
- Strengthening partnerships with IVF clinics, lab equipment manufacturers, and fertility networks to accelerate adoption.
Key advancements include:
- AI-Driven Embryo and Follicle Analysis: Introducing machine learning models that assist in embryo selection and follicle monitoring, improving the accuracy and reliability of IVF procedures.
- Integration with IVF Workflows: Seamless incorporation into laboratory and clinical environments, enhancing efficiency and reducing embryologists’ workload.
- Scientific Validation and Ethical AI Practices: Backed by a Scientific Advisory Board (SAB) of leading reproductive medicine specialists to ensure credibility and compliance with industry best practices.
Potential Impact and Future Needs
1. Further Research and Validation:
- Conducting large-scale clinical studies to assess AI’s long-term impact on IVF success rates.
- Continuous model refinement with real-world clinical data to enhance AI performance and accuracy.
2. Commercialization and Market Adoption:
- Expanding regulatory approvals, including CE marking (EU) and FDA clearance (US).
- Strengthening partnerships with IVF clinics, lab equipment manufacturers, and fertility networks to accelerate adoption.